We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bio-Nano-Micro-Informatic Technologies Developed to Help Diagnose DVT and PE

By Labmedica staff writers
Posted on 07 Jan 2008
A European consortium is developing new bio-nano-micro-informatic technologies that will ultimately help clinicians rapidly diagnose patients suspected of deep vein thrombosis (DVT) and pulmonary embolism (PE) at the point-of-first-contact.

Ten European research and high-tech firms are developing a reliable, accurate, mobile, handheld, medical diagnostic prototype device that can be used to rapidly diagnose patients suspected of DVT and PE. More...
Using the latest developments in polymer electronics, biomolecular engineering, lab-on-a-chip, wireless information communications technology (ICT), and nano-bio-technologies, the prototype device will detect D-dimer levels in whole blood. These levels will indicate to healthcare professionals whether they should rule out DVT or refer the patient for further diagnosis. A prototype device will be ready in August of 2009.

The device is expected to improve the speed, accuracy, and reliability with which DVT and related blood clot conditions can be diagnosed at the point-of-first-contact and will enable practitioners to reduce the number of false-positive diagnoses. It will be used at primary point-of-care (POC) locations including hospitals, local clinics, accident and emergency units, doctors' offices, outpatient departments, and by paramedics.

The University of Teesside (Tees Valley, UK) is leading the consortium, which also includes Cenamps (New Castle upon Tyne, UK), Helena Biosciences (Gateshead, UK), Wyeth (Madison, NJ, USA), Fraunhofer Institute (München, Germany), and other companies and universities in Spain, France, Slovakia, and Hungary.


Related Links:
Cenamps
Helena Biosciences
Fraunhofer Institute

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Electrolyte Analyzer
CBS-4000 (CBS-400)
New
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.